With over 70 years of pharmaceutical heritage and one of the largest international operational footprints in the Turkish healthcare sector, Nobel İlaç has updated its commercial organizational model to capture evolving therapeutic needs and market opportunities.
The new framework aims to protect the market share of established legacy portfolios while building scalable commercial platforms in specialized therapies, nephrology, hepatology, and healthy longevity.
Four Core Directorates and Executive Appointments
The newly established leadership appointments include:
Primary Care Directorate: Bahri Karayaka, formerly Cardiology 2 Business Unit Manager, has been promoted to Primary Care Director.
Specialty Care Directorate: Ali Engin, previously serving as Cardiology 1 Business Unit Manager, has been appointed Specialty Care Director.
Specialized Products Directorate: Kemal Özkan, former Business Unit Manager for Hepatology, Nephrology, and Rare Diseases 2, has been named Specialized Products Director.
Nobel Longevity Directorate: Özer Sinan Yalanuz, previously Head of the Nobel Longevity Business Unit, assumes the role of Nobel Longevity Director.
Central Nervous System (CNS) Marketing: Concurrently, Duygu Değirmenci has been named Marketing Manager for Central Nervous System therapies.
The appointment of leaders who developed their professional careers within Nobel İlaç reflects the company's human capital strategy centered on talent retention and internal succession planning.
